Showing results (311-320 of 463) with videos related to

Sort By:
Pageof 47
Clinical Pharmacokinetics|September 16, 2023
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1Mirjam de With, Leni van Doorn, Esmay Kloet, et al.
Journal of the Peripheral Nervous System : JPNS|December 26, 2022
The effect of tremor on disability assessment in chronic inflammatory demyelinating polyradiculoneuropathyR van Veen, G Pallada, L Wieske, et al.
European Journal of Neurology|August 4, 2026
The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating PolyradiculoneuropathyIris N van Doorn, Adája E Baars, Luuk Wieske, et al.
Pharmacogenetics and Genomics|March 13, 2008
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipientsDennis A Hesselink, Ron H N van Schaik, Madelon van Agteren, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2005
A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levelsPauline Smit, Ron H N van Schaik, Marloes van der Werf, et al.
Breast Cancer Research and Treatment|June 6, 2013
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentK Beelen, M Opdam, T M Severson, et al.
Pharmacogenetics and Genomics|March 13, 2008
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentrationAlbert-Jan L H J Aarnoudse, Jeanne P Dieleman, Loes E Visser, et al.
Clinical Pharmacokinetics|July 7, 2017
A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal TransplantationLouise M Andrews, Dennis A Hesselink, Teun van Gelder, et al.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Pharmacogenomics|October 11, 2014
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarctionMaarten Leusink, Catherine E de Keyser, N Charlotte Onland-Moret, et al.
Pageof 47